Elizabeth Nugent, MD
Gynecologic Oncology · Houston, TXNPI 1841396116
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $281 of the $381 with a category attached, or 73.8%. 9 manufacturers reported payments, led by Seagen Inc. at 26.2% of the total. Reporting peaked in 2024 at $182 and has fallen 55.8% since, to $80 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in TX, where the typical reported total is $3,034.
Across 12 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$100
- Baxter Healthcare$60
- Merck$56
- Genmab U.S., Inc.$48
- Resmed Corp$34
- Smith+Nephew$31
- plus $51 from 3 others
What the payments were for
- Food & beverage$28174%
- Education$10026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 1 | $100 |
| Baxter Healthcare | 1 | $60 |
| Merck | 2 | $56 |
| Genmab U.S., Inc. | 2 | $48 |
| Resmed Corp | 2 | $34 |
| Smith+Nephew | 1 | $31 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Boston Scientific | 1 | $16 |
| Coopersurgical, Inc. | 1 | $12 |
How this compares
$381 in reported general payments places this provider in the 10th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $11,789 |
| Ondansetron Hcl | 23 | $5,904 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $822 |
| Prochlorperazine Maleate | 19 | $496 |
| Oxycodone Hcl | 21 | $230 |
| Gabapentin | 20 | $225 |
| Methadone Hcl | 14 | $155 |
| Ibuprofen | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Houston
- Robert ColemanHouston$864K
- Maurie MarkmanHouston$204K
- Michael FrumovitzHouston$156K
- Aparna KamatHouston$116K
- Anuj SuriHouston$72K
- Anil SoodHouston$69K
- Pedro RamirezHouston$42K
- Pamela SolimanHouston$37K
- Anthony CostalesHouston$17K
- Travis SimsHouston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.